PND38 Cost Minimization Analysis of Fingolimod Versus Natalizumab in the Second-Line Treatment of Remittent-Recurrent Multiple Sclerosis

Saved in:
Bibliographic Details
Published in:Value in health 2012-11, Vol.15 (7), p.A552-A552
Main Authors: Crespo, C, Izquierdo, G, García-Ruiz, A, Granell, M, Brosa, M
Format: Article
Language:English
Subjects:
Internal Medicine
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:1098-3015
1524-4733
DOI:10.1016/j.jval.2012.08.1962